Key statistics
On Wednesday, Myriad Genetics Inc (MYGN:NSQ) closed at 5.28, 40.43% above the 52 week low of 3.76 set on Aug 01, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 5.30 |
|---|---|
| High | 5.49 |
| Low | 5.26 |
| Bid | 5.20 |
| Offer | 5.45 |
| Previous close | 5.29 |
| Average volume | 2.22m |
|---|---|
| Shares outstanding | 93.51m |
| Free float | 90.75m |
| P/E (TTM) | -- |
| Market cap | 494.66m USD |
| EPS (TTM) | -3.95 USD |
Data delayed at least 15 minutes, as of Mar 04 2026 21:00 GMT.
More ▼
- Myriad Commercially Launches Precise MRD with Select Community Oncologists
- Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
- Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
- FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
- Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
- Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
- Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
- Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
- Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
- Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
More ▼
